Jonathan Aschoff
Stock Analyst at Roth Capital
(0.50)
# 4,008
Out of 4,910 analysts
44
Total ratings
24.53%
Success rate
-35.28%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTRK Ontrak | Maintains: Buy | $4 → $3 | $0.57 | +426.41% | 3 | Jul 9, 2025 | |
| GTBP GT Biopharma | Initiates: Buy | $11 | $1.99 | +454.16% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $11.58 | +81.43% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $11,100 → $5,920 | $3.13 | +189,037.38% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.66 | +984.34% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $14.33 | +4,882.55% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $0.82 | +2,339.02% | 1 | Jul 16, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Maintains: Buy | $5,040 → $2,640 | $10.76 | +24,435.32% | 2 | May 3, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $40 | $0.78 | +5,057.30% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $5.20 | +16,053.85% | 4 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $36 | $9.64 | +273.44% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3,750 → $18,000 | $8.30 | +216,767.47% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $6.02 | +398.34% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $3.81 | +5,149.34% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $2.88 | +386.11% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7,200 → $21,600 | $3.05 | +708,096.72% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.03 | +676.70% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.74 | +3,549.64% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.92 | +43,501.48% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $6.00 | +533.33% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $360,000 | $5.20 | +6,922,976.92% | 1 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $1.45 | +6,520.69% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $2.40 | +441.67% | 1 | Dec 19, 2019 |
Ontrak
Jul 9, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.57
Upside: +426.41%
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $1.99
Upside: +454.16%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $11.58
Upside: +81.43%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $11,100 → $5,920
Current: $3.13
Upside: +189,037.38%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.66
Upside: +984.34%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $14.33
Upside: +4,882.55%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $0.82
Upside: +2,339.02%
Cyclacel Pharmaceuticals
May 3, 2024
Maintains: Buy
Price Target: $5,040 → $2,640
Current: $10.76
Upside: +24,435.32%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $0.78
Upside: +5,057.30%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $5.20
Upside: +16,053.85%
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $9.64
Upside: +273.44%
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $8.30
Upside: +216,767.47%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $6.02
Upside: +398.34%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $3.81
Upside: +5,149.34%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $2.88
Upside: +386.11%
Feb 14, 2023
Maintains: Buy
Price Target: $7,200 → $21,600
Current: $3.05
Upside: +708,096.72%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.03
Upside: +676.70%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $2.74
Upside: +3,549.64%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.92
Upside: +43,501.48%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $6.00
Upside: +533.33%
Feb 12, 2021
Initiates: Buy
Price Target: $360,000
Current: $5.20
Upside: +6,922,976.92%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $1.45
Upside: +6,520.69%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $2.40
Upside: +441.67%